Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Thyroid Neoplasms 3Thyroid Cancer, Papillary 2Adenocarcinoma, Follicular 2Thyroid Diseases 1Prostatic Neoplasms 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Head and Neck Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

romidepsin 8Vincristine 6Cyclophosphamide 6Specimen Handling 5Rituximab 5Biopsy 5fludarabine 4Prednisone 4Methotrexate 4Magnetic Resonance Spectroscopy 4Lactones 4Doxorubicin 4Depsipeptides 4ruxolitinib 3duvelisib 3belinostat 3Nivolumab 3Etoposide 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3Bortezomib 3Azacitidine 3tazemetostat 2sodium-iodide symporter 2pegaspargase 2merphos 2liposomal doxorubicin 2cemiplimab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell × Iodine-131 × Clear all
NCT00860171 2020-04-03

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Terminated
16 enrolled 10 charts
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡